ATE401066T1 - Methoden zur behandlung der essstörungen - Google Patents

Methoden zur behandlung der essstörungen

Info

Publication number
ATE401066T1
ATE401066T1 AT00918073T AT00918073T ATE401066T1 AT E401066 T1 ATE401066 T1 AT E401066T1 AT 00918073 T AT00918073 T AT 00918073T AT 00918073 T AT00918073 T AT 00918073T AT E401066 T1 ATE401066 T1 AT E401066T1
Authority
AT
Austria
Prior art keywords
eating disorders
methods
treating eating
treating
nervosa
Prior art date
Application number
AT00918073T
Other languages
English (en)
Inventor
Carl Mendel
Timothy SEATON
Steve Weinstein
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22418412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE401066(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of ATE401066T1 publication Critical patent/ATE401066T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00918073T 1999-03-19 2000-03-17 Methoden zur behandlung der essstörungen ATE401066T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12515099P 1999-03-19 1999-03-19

Publications (1)

Publication Number Publication Date
ATE401066T1 true ATE401066T1 (de) 2008-08-15

Family

ID=22418412

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00918073T ATE401066T1 (de) 1999-03-19 2000-03-17 Methoden zur behandlung der essstörungen

Country Status (23)

Country Link
US (1) US6365633B1 (de)
EP (1) EP1178789B1 (de)
JP (1) JP2003519087A (de)
KR (1) KR100432825B1 (de)
CN (1) CN1188120C (de)
AT (1) ATE401066T1 (de)
AU (1) AU773188C (de)
BR (1) BR0009026A (de)
CA (1) CA2367666C (de)
CZ (1) CZ20013278A3 (de)
DE (1) DE60039508D1 (de)
ES (1) ES2307501T3 (de)
HK (1) HK1045455B (de)
HU (1) HUP0200495A3 (de)
IL (1) IL145240A (de)
MX (1) MXPA01009404A (de)
NO (1) NO20014479L (de)
NZ (1) NZ514011A (de)
PL (1) PL351963A1 (de)
SK (1) SK12992001A3 (de)
TR (1) TR200102646T2 (de)
WO (1) WO2000054765A1 (de)
ZA (1) ZA200107533B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
CN1902177A (zh) 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
CA2577060A1 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
BRPI0518241A (pt) 2004-11-01 2008-04-22 Amylin Pharmaceuticals Inc métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
AU2006277253A1 (en) 2005-08-10 2007-02-15 Msd K.K. Pyridone compound
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
JPWO2007029847A1 (ja) 2005-09-07 2009-03-19 萬有製薬株式会社 二環性芳香族置換ピリドン誘導体
EP1938811A4 (de) * 2005-09-22 2008-12-17 Eisai R&D Man Co Ltd Medizinische zusammensetzung zur behandlung von bulimie und mit bulimie einhergehenden depressionen
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CN101291662A (zh) 2005-10-21 2008-10-22 诺瓦提斯公司 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合
WO2007049798A1 (ja) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. 新規ベンゾオキサチイン誘導体
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
EP2083831B1 (de) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Verfahren zur behandlung von fettsäure-synthese-hemmern
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
TWI440456B (zh) 2007-01-16 2014-06-11 用於治療代謝性症候群之新穎化合物
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
CN101939022A (zh) * 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2379562A1 (de) 2008-12-16 2011-10-26 Schering Corporation Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3243385B1 (de) 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Neue cyclische azabenzimidazolderivate als antidiabetika
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
CN104994848A (zh) 2013-02-22 2015-10-21 默沙东公司 抗糖尿病二环化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PT3004138T (pt) 2013-06-05 2024-06-18 Bausch Health Ireland Ltd Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
EP3526199B1 (de) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitoren der alpha-amino-beta-carboxymuconsäure-semialdehyddecarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CA3119509A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
JP2001524960A (ja) * 1997-04-24 2001-12-04 メルク シヤープ エンド ドーム リミテツド 摂食障害を治療するためのｎｋ−１受容体拮抗薬の使用
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
MXPA01007388A (es) * 1999-01-20 2002-07-22 Knoll Gmbh Metodo para ayudar a dejar de fumar.
DK1158973T3 (da) * 1999-02-24 2005-05-30 Univ Cincinnati Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser

Also Published As

Publication number Publication date
BR0009026A (pt) 2003-03-05
AU3894700A (en) 2000-10-04
HK1045455B (zh) 2009-04-09
EP1178789A1 (de) 2002-02-13
HK1045455A1 (en) 2002-11-29
CA2367666C (en) 2008-11-25
HUP0200495A3 (en) 2004-09-28
KR20020063107A (ko) 2002-08-01
AU773188B2 (en) 2004-05-20
CZ20013278A3 (cs) 2002-07-17
CN1188120C (zh) 2005-02-09
DE60039508D1 (de) 2008-08-28
TR200102646T2 (tr) 2002-08-21
NO20014479D0 (no) 2001-09-14
IL145240A (en) 2007-02-11
ES2307501T3 (es) 2008-12-01
HUP0200495A2 (en) 2002-08-28
IL145240A0 (en) 2002-06-30
KR100432825B1 (ko) 2004-05-24
CN1365276A (zh) 2002-08-21
EP1178789B1 (de) 2008-07-16
CA2367666A1 (en) 2000-09-21
NO20014479L (no) 2001-11-02
AU773188C (en) 2006-01-05
EP1178789A4 (de) 2004-02-18
MXPA01009404A (es) 2004-03-19
NZ514011A (en) 2001-09-28
SK12992001A3 (sk) 2002-03-05
ZA200107533B (en) 2002-12-12
WO2000054765A1 (en) 2000-09-21
WO2000054765A8 (en) 2002-05-23
JP2003519087A (ja) 2003-06-17
US6365633B1 (en) 2002-04-02
PL351963A1 (en) 2003-07-14

Similar Documents

Publication Publication Date Title
ATE401066T1 (de) Methoden zur behandlung der essstörungen
ATE324371T1 (de) N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
CZ305838B6 (cs) N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6
DK0773943T3 (da) Forbindelser, der er anvendelige som antiproliferative midler og garft-inhibitorer
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
NO980919D0 (no) 8-azabicyklo(3.2.1)okt-2-ene derivater, deres fremstilling og anvendelse
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
ATE308522T1 (de) Opioidrezeptorantagonisten
BRPI0407841A (pt) inibidores heterocìclicos de quinase
RS20060239A (en) Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics
WO2000056315A8 (en) Treatment of pain
DK1169029T3 (da) Anvendelse af sibutramin eller et derivat deraf til behandling af sövnforstyrrelser
SE0103795D0 (sv) Compounds and method for the treatment of överactive bladder
NO20063299L (no) Syntese av en polymorf av 4-amino-5-klor-2-metoksy-N-(1-azabisyklo[3.3.1]non-4-yl)benzamidhydrokloridhydrat
BG105996A (en) Method of treating eating disorders
MXPA01009469A (es) Tratamiento para disminuir la adhesividad de las plaquetas.
MXPA01009461A (es) Tratamiento de osteoartritis.
MXPA01009468A (es) Tratamiento de hipertension pulmonar.
SE0103668D0 (sv) Method for the treatment of overactive blader
MXPA01009463A (es) Tratamiento de hernia hiatial.
MXPA01009465A (es) Perdida de peso despues del embarazo.
DE60208347D1 (de) Verwendung von "xylyloxy alkyl amines" für die Behandlung von Tinnitus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties